About perrinThis author has not yet filled in any details.
So far perrin has created 12 blog entries.
Date: November 16 to 18
Venue: In-person, Waikiki Beach Marriot Resort, Honolulu, HI
CanPath Webinar with Dr. John Lewis
WEBINAR TO BE RESCHEDULED
Webinar: Predicting diseases through machine learning models
Date: Tuesday, November 22. 2022. New date TBD – please check back for updates.
Venue: Online – for more details and to register go to Event Link
Can Machine Learning models predict disease? Dr. John Lewis, Bird Dogs Chair in Translational Oncology at the University of Alberta, and CEO of Nanostics will talk about creating disease prediction models using CanPath questionnaire data, to help us understand the global risk factors of diseases like prostate cancer and how these risk factors differ for different populations.
What: Nanostics’ CTO Robert Paproski will present “Lessons Learned Developing Predictive Models for Healthcare”
When: September 2, 12-1 pm MT
Go here to access the zoom link and password (scroll to Sept 2) https://sites.google.com/ualberta.ca/ai-seminar/upcoming-seminars
Over the past decade, significant interest has developed for using machine learning in medical devices for assisting in the diagnosis and risk prediction of diseases. Many publications have demonstrated promising preliminary results although the path of deploying a predictive model in the clinic is challenging from a technological and regulatory perspective. This presentation will discuss Nanostics’ work developing ClarityDX Prostate, a medical device which predicts clinically significant prostate cancer, including the challenges of obtaining FDA approval. Training predictive models on large, diverse, clinical datasets is vital for developing trustworthy models although obtaining such datasets can be problematic. Potential solutions for working with large clinical datasets will be discussed.
Press Release: Nanostics Receives CE Mark for its ClarityDX Prostate® Test to Detect Clinically Significant Prostate Cancerperrin2022-08-23T12:18:30+00:00
Press Release: Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancerperrin2022-07-20T13:09:06+00:00
Press Release: Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancerperrin2022-06-30T12:14:03+00:00
Small particle flow cytometry using 3 light scatter detectors enhances extracellular vesicle analysis in liquid biopsies, highlighting the potential to segregate EVs by refractive index
Pink, Desmond, Basu, Arghya, Valencia, Juliana, Pham, Diana, and Lewis, J.D.
Extracellular vesicle analysis using “small particle” flow cytometry would be greatly enhanced if data from materials of different refractive index (RI) could be segregated. Likewise, relative sizing of EVs using small particle flow cytometry is confounded by the influence of RI on light scatter. Beads of different composition and refractive index scatter light differently, so that small beads of high RI and large beads of lower RI can have overlapping signals on a two dimension light scatter plot. As particle size decreases, light scatter intensity profiles eventually merge regardless of refractive index. In this project, we aimed to demonstrate graphically, (1) the enhancement of EV flow analysis when using an additional angle of light scatter collection (medium angle of light scatter, MALS) to identify different sample components (e.g. lipids, protein, extracellular vesicles) and (2) the practical reality of sample component overlap at different particle sizes.
Nanostics CSO Desmond Pink will be presenting this work at CYTO 2022, June 3-7, in Philadelphia, US.
CYTO 2022 MOVING FORWARD
Empowering Scientists. Advancing Cytometry.
LIFE SCIENCES SUMMIT FINALE
Date: Thu, March 17, 2022 at 3:30 PM – 7:30 PM MDT
Venue: Online and in-person for more details and to register go to Eventbrite.
5 Pitches. 1 massive Zoom party. 4 in-person afterparties.
CCO Colin Coros will take part in the pre-game show: “Get to Know the Investors, What’s Happening in Life Sciences Anyway, and Why I’m Building It Here”